Literature DB >> 20211659

Granins and granin-related peptides in neuroendocrine tumours.

Guida M Portela-Gomes1, Lars Grimelius, Erik Wilander, Mats Stridsberg.   

Abstract

This review focus on neuroendocrine tumours (NETs), with special reference to the immunohistochemical analysis of granins and granin-related peptides and their usefulness in identifying and characterizing the great diversity of NET types. Granins, their derived peptides, and complex protein-processing enzyme systems that cleave granins and prohormones, have to some extent cell-specific expression patterns in normal and neoplastic NE cells. The marker most commonly used in routine histopathology to differentiate between non-NETs and NETs is chromogranin (Cg) A, to some extent CgB. Other members of the granin family may also be of diagnostic value by identifying special NET types, e.g. secretogranin (Sg) VI was only found in pancreatic NETs and phaeochromocytomas. SgIII has recently arisen as an important NET marker; it was strongly expressed in NETs, with some exceptions--phaeochromocytomas expressed few cells and parathyroid adenomas none. Some expression patterns of granin-related peptides seem valuable in differentiating between some benign and malignant NETs, some may also provide prognostic information, among which: well-differentiated NET types expressed more CgA epitopes than the poorly differentiated ones, except insulinomas, where the opposite was noted; medullary thyroid carcinomas containing few cells immunoreactive to a CgB antibody were related to a bad prognosis; C-terminal secretoneurin visualized a cell type related to malignancy in phaeochromocytomas. Further research will probably establish new staining patterns with marker functions for granins in NETs which may be of histopathological diagnostic value.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20211659     DOI: 10.1016/j.regpep.2010.02.011

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  26 in total

1.  Integrative proteomics and transcriptomics identify novel invasive-related biomarkers of non-functioning pituitary adenomas.

Authors:  Sheng-Yuan Yu; Li-Chuan Hong; Jie Feng; You-Tu Wu; Ya-Zhuo Zhang
Journal:  Tumour Biol       Date:  2016-01-11

Review 2.  Immunohistochemical and biochemical studies with region-specific antibodies to chromogranins A and B and secretogranins II and III in neuroendocrine tumors.

Authors:  Guida M Portela-Gomes; Lars Grimelius; Mats Stridsberg
Journal:  Cell Mol Neurobiol       Date:  2010-11-03       Impact factor: 5.046

Review 3.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

Review 4.  Chromogranin A and derived peptides in health and disease.

Authors:  Y Peng Loh; Yong Cheng; Sushil K Mahata; Angelo Corti; Bruno Tota
Journal:  J Mol Neurosci       Date:  2012-03-03       Impact factor: 3.444

5.  Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome.

Authors:  Allison B Weisbrod; Mio Kitano; Francine Thomas; David Williams; Neelam Gulati; Krisana Gesuwan; Yixun Liu; David Venzon; Ismail Turkbey; Peter Choyke; Jack Yao; Steven K Libutti; Naris Nilubol; William M Linehan; Electron Kebebew
Journal:  J Am Coll Surg       Date:  2013-11-12       Impact factor: 6.113

6.  Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Pancreas       Date:  2012-05       Impact factor: 3.327

Review 7.  Chromogranin A: a paradoxical player in angiogenesis and vascular biology.

Authors:  Karen B Helle; Angelo Corti
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

Review 8.  Chromogranin A and the tumor microenvironment.

Authors:  Angelo Corti
Journal:  Cell Mol Neurobiol       Date:  2010-11-16       Impact factor: 5.046

9.  Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.

Authors:  Allison B Weisbrod; Lisa Zhang; Meenu Jain; Stephanie Barak; Martha M Quezado; Electron Kebebew
Journal:  Horm Cancer       Date:  2013-01-30       Impact factor: 3.869

Review 10.  Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.

Authors:  Angelo Corti; Fabrizio Marcucci; Tiziana Bachetti
Journal:  Pflugers Arch       Date:  2017-10-10       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.